Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

In a regulatory filing, Opko Health (OPK) disclosed that its CEO Phillip Frost bought 200K shares of common stock on March 17th in a total ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y.

Vertical Aerospace • EVTL-NYSE Buy • $3.39 on March 12 by Canaccord Genuity We are maintaining our Buy rating on shares of ...

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth ...

Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for ...

HC Wainwright reissued their buy rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $3.00 price objective on the ...